Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (09989.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenHKD 4.22

From 52W high−36.91%

Volume2.39M

Market capHKD 5.52B

P/E (TTM)23.0x

P/S (TTM)0.9x

Div yield4.42%

Key dataSep 18, 2026

Open

HKD 4.22

From 52W high

−36.91%

Volume

2.39M

Market cap

HKD 5.52B

ValuationView details →

P/E (Fwd)

11.0x

EV/EBITDA

11.7x

P/E (TTM)

23.0x

RSI (14)

28.3

MomentumView details →

1D Return

−9.51%

YTD Return

−27.83%

ValuationView details →

P/E (Fwd)

11.0x

P/E (TTM)

23.0x

EV/EBITDA

11.7x

EV/Sales

0.8x

P/S (TTM)

0.9x

P/B (TTM)

0.4x

ProfitabilityView details →

Gross Margin

33.33%

Net Margin

3.87%

EBITDA Margin

6.71%

ROE (TTM)

1.70%

ROA (TTM)

1.24%

Asset Turnover

0.31x

GrowthView details →

Revenue YoY

−0.37%

EPS YoY

−49.87%

FCF YoY

−19.01%

Revenue CAGR 3Y

−8.53%

EPS CAGR 3Y

−21.70%

EBITDA YoY

−35.31%

MomentumView details →

1D Return

−9.51%

YTD Return

−27.83%

1Y Return

−33.69%

RSI (14)

28.3

vs 50D SMA

−12.62%

vs 200D SMA

−21.02%

Capital & dividendView details →

Debt/Equity

0.24x

Current Ratio

2.31x

Quick Ratio

1.33x

Div Yield

4.42%

Div Rate

HKD 0.17

Div Growth 1Y

−38.88%

EarningsView details →

EPS (Actual)

HKD 0.07

EPS Surprise

−24.68%

Beats (12Q)

0/12

Next Q EPS Est

HKD 0.22

Avg Surprise (4Q)

−24.68%

Rev Surprise

−9.85%

Financials snapshotView financials →

Revenue (TTM)

5.24B

Net Income (TTM)

202.88M

Op. CF (TTM)

1.50B

Next earningsNov 4, 2026 →

Latest newsMore news →

Hepalink announced its H1 2026 results: revenue of 2.58 billion yuan, down 8.44% year-on-year; net profit attributable to shareholders of 275 million yuan, down 34.74% year-on-year; non-GAAP net profit of 162 million yuan, down 62.01% year-on-year. The company plans no cash dividend, no bonus shares, and no capital reserve conversion.23d ago

Similar companies

津药药业600488.SH 人民同泰600829.SH 圣诺生物688117.SH 华纳药厂688799.SH 吉贝尔688566.SH Amneal Pharmaceuticals, Inc.AMRX Find similar companies →

Latest newsMore news →

Hepalink announced its H1 2026 results: revenue of 2.58 billion yuan, down 8.44% year-on-year; net profit attributable to shareholders of 275 million yuan, down 34.74% year-on-year; non-GAAP net profit of 162 million yuan, down 62.01% year-on-year. The company plans no cash dividend, no bonus shares, and no capital reserve conversion.23d ago